Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI1873 · 1 trial · 1 indication
The maximum tolerated dose (MTD)/highest protocol-defined dose level in the absence of establishing an MTD will be determined by the number of participants experiencing DLTs. The safety profile will be assessed through number of participants experiencing AEs, SAEs, DLTs, abnormal laboratory parameters, vital signs and electrocardiogram (ECG) results.
| Arm | Type | Description |
|---|---|---|
| Monotherapy arm | EXPERIMENTAL | MEDI1873 |
| Name | Type | Description |
|---|---|---|
| MEDI1873 | BIOLOGICAL | Subjects will receive MEDI1873 by intravenous administration |
Inclusion Criteria: * All subjects must consent to provide archived tumor specimen * Subjects must have histologically or cytologically confirmed advanced solid tumor for recurrent or metastatic disease. * At the time of Day 1 of the study, subjects with central nervous system (CNS) metastases must...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MEDI1873 is an investigational monoclonal antibody being developed by AstraZeneca PLC for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development.
MEDI1873 is being studied for the treatment of advanced solid tumors. The clinical trial enrolled adult subjects with select advanced solid tumors.
MEDI1873 is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are no active trials currently ongoing.
The trial, NCT02583165, was a Phase 1 study in adult subjects with select advanced solid tumors. It was conducted in the United States, enrolled 40 participants, and was uncontrolled, meaning there was no control group. The trial has been completed.
Eligible participants were adults aged 18 years and older with advanced solid tumors. Both males and females were eligible, and healthy volunteers were not included in the study.
No, the Phase 1 trial for MEDI1873 was not randomized and was not double-blinded. It was an uncontrolled study, meaning all participants received the same treatment without a comparison group.